Tregalizumab is a human monoclonal antibody that binds to a unique epitope of CD4. Tregalizumab has been used in the research of autoimmune diseases, including rheumatoid arthritis (RA).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.